<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute asthma exacerbations in children younger than 12 years: Inpatient management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute asthma exacerbations in children younger than 12 years: Inpatient management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute asthma exacerbations in children younger than 12 years: Inpatient management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Sawicki, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenan Haver, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Redding, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>More than 6.5 million children in the United States have asthma [<a href="#rid1">1</a>], which accounts for nearly 550,000 emergency department (ED) visits, 2,500,000 clinician office visits, and 80,000 hospitalizations each year [<a href="#rid2">2,3</a>]. Although exacerbations are common, most are mild and can be managed successfully at home. Children with severe exacerbations or those who fail to improve with outpatient therapy may need to be evaluated and treated in an urgent care facility or ED, and some will need to be admitted to the hospital for further management.</p><p>Inpatient management of acute asthma exacerbations in children is discussed here. Outpatient and intensive care unit (ICU) management are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Most children who require admission for asthma are initially treated in the emergency department (ED), although some are admitted directly from clinicians' offices. Thus, inpatient treatment is typically a continuation of therapies and monitoring that were started in the ED  (<a class="graphic graphic_algorithm graphicRef123081" href="/d/graphic/123081.html" rel="external">algorithm 1</a>) [<a href="#rid4">4</a>]. Patients usually have received at least three <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> treatments, often combined with <a class="drug drug_pediatric" data-topicid="13389" href="/d/drug information/13389.html" rel="external">ipratropium</a>, systemic glucocorticoids, and supplemental oxygen, before arrival to the inpatient unit. The criteria for admission are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Hospitalization'</a>.)</p><p>Communication among the referring clinicians, providers in the ED, and those caring for the patient in the hospital is essential to ensure that treatments ordered in the ED are not missed or duplicated during the transfer of care.</p><p>Inpatient management consists of [<a href="#rid5">5-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Initial clinical assessment followed by ongoing monitoring for change in clinical status (see <a class="local">'Initial assessment and ongoing monitoring'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of bronchospasm, inflammation, and hypoxemia with inhaled short-acting beta agonists (SABAs; such as <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a>/salbutamol) and <a class="drug drug_pediatric" data-topicid="13389" href="/d/drug information/13389.html" rel="external">ipratropium</a>, systemic glucocorticoids, and supplemental oxygen, respectively (see <a class="local">'Management of bronchospasm'</a> below and <a class="local">'Management of inflammation'</a> below and <a class="local">'Management of hypoxemia'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discharge planning, including asthma education, assessment for medication equipment need, and initiation or adjustment of controller agents, based upon classification of severity and/or control prior to discharge  (<a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/d/graphic/127785.html" rel="external">table 1A-B</a>) (see <a class="local">'Discharge criteria'</a> below and  <a class="medical medical_review" href="/d/html/5744.html" rel="external">"Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"</a> and  <a class="medical medical_review" href="/d/html/90904.html" rel="external">"Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"</a>)</p><p></p><p class="headingAnchor" id="H2482027781"><span class="h1">INITIAL ASSESSMENT AND ONGOING MONITORING</span><span class="headingEndMark"> — </span>Clinical status and response to therapy must be monitored frequently during treatment for acute asthma exacerbation [<a href="#rid5">5,9-17</a>]. The degree of monitoring depends upon the severity of the exacerbation and the treatments required. The most important parts of the clinical evaluation include assessment of respiratory rate, work of breathing (retractions), pulse oximetry, and the lung exam. Heart rate and rhythm need to be followed given the risk of <em>cardiac side effects (</em>tachycardia and less common but more severe cardiac side effects including diastolic hypotension, cardiac dysrhythmias, and myocardial ischemia) with beta agonists [<a href="#rid18">18-22</a>]. Asthma scores can be used to evaluate response to treatment. Pulmonary function testing, chest radiographs, and laboratory studies are of limited use in most children hospitalized for asthma exacerbations. (See  <a class="medical medical_review" href="/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management", section on 'Severity assessment'</a> and  <a class="medical medical_review" href="/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Assessment of exacerbation severity'</a>.)</p><p>Administration of supplemental oxygen (100 percent fraction of inspired oxygen [FiO<sub>2</sub>], given either separately or with nebulized medications) may mask worsening asthma and delay recognition until the episode is more severe and potentially life threatening. Thus, parameters other than pulse oximetry should be relied upon to assess deterioration in patients on supplemental oxygen.</p><p class="headingAnchor" id="H2567988109"><span class="h2">Clinical assessment</span><span class="headingEndMark"> — </span>The clinical evaluation includes assessment of:</p><p class="bulletIndent1"><span class="glyph">●</span>Vital signs, particularly the respiratory rate</p><p class="bulletIndent1"><span class="glyph">●</span>Accessory muscle use</p><p class="bulletIndent1"><span class="glyph">●</span>Wheezing</p><p class="bulletIndent1"><span class="glyph">●</span>Inspiratory-to-expiratory ratio</p><p class="bulletIndent1"><span class="glyph">●</span>Pulse oximetry</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea</p><p class="bulletIndent1"><span class="glyph">●</span>Ability to complete full sentences</p><p class="bulletIndent1"><span class="glyph">●</span>Level of consciousness</p><p></p><p class="headingAnchor" id="H1925384774"><span class="h3">Signs of impending respiratory failure</span><span class="headingEndMark"> — </span>Signs of impending respiratory failure include  (<a class="graphic graphic_table graphicRef76344" href="/d/graphic/76344.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Cyanosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Marked tachypnea or inability to maintain respiratory effort due to fatigue and/or poor air movement with a prolonged expiratory phase (respiratory rate may be inappropriately normal to low and breath sounds reduced or inaudible)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Change in mental status (eg, lethargy, agitation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Worsening hypoxemia (peripheral arterial oxygen saturation [SpO<sub>2</sub>] &lt;90 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Carbon dioxide retention (partial pressure of CO<sub>2</sub> [PaCO<sub>2</sub>] &gt;40 mmHg) (see <a class="local">'Laboratory studies'</a> below)</p><p></p><p>These patients should be transferred to the pediatric intensive care unit (PICU). (See  <a class="medical medical_review" href="/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"</a>.)</p><p class="headingAnchor" id="H1338586812"><span class="h3">Frequency and extent of evaluation</span><span class="headingEndMark"> — </span>Patients should be assessed immediately upon arrival to the inpatient unit. Clinical findings should be compared with those obtained in the emergency department (ED) to determine whether the patient is improving or worsening.</p><p>Monitoring protocols vary from institution to institution and also depend upon the patient's clinical status and level of treatment. On an inpatient unit, patients are typically evaluated before and after treatments when on intermittent therapy or every one to two hours while receiving continuous inhaled beta agonist therapy to determine their response to therapy. Patients receiving continuous inhaled beta agonist therapy additionally should be on continuous cardiopulmonary monitoring. Such monitoring should be continued until the patient is tolerating interval treatments every three hours, at which time the patient can be switched to intermittent monitoring. The frequency of monitoring vital signs and oxyhemoglobin saturation are decreased as the patient improves and inhalation treatments are spaced to every four hours. At minimum, vital signs and oxygen saturation should be assessed every four hours.</p><p>Monitoring and therapy adjustment for inhaled beta agonists and supplemental oxygen is discussed in greater detail below. (See <a class="local">'Therapy adjustment'</a> below and <a class="local">'Management of hypoxemia'</a> below.)</p><p class="headingAnchor" id="H1498690378"><span class="h3">Asthma scores</span><span class="headingEndMark"> — </span>Several scoring systems have been developed to standardize and facilitate assessment of initial severity of an asthma exacerbation in children. These scores also can be used to evaluate the response to treatment and guide changes in the frequency of bronchodilator (beta agonist) administration. These scores are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Assessment of severity'</a> and  <a class="medical medical_review" href="/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Asthma severity scores'</a>.)</p><p class="headingAnchor" id="H1030690672"><span class="h2">Studies reserved for select patients</span></p><p class="headingAnchor" id="H3961738917"><span class="h3">Pulmonary function testing</span><span class="headingEndMark"> — </span>We generally do not use pulmonary function measurements to monitor children with acute exacerbations. Pulmonary function testing may be useful in the cooperative child, once stabilized, whose asthma diagnosis or level of control is in doubt. (See  <a class="medical medical_review" href="/d/html/5735.html" rel="external">"Overview of pulmonary function testing in children", section on 'Spirometry'</a>.)</p><p class="headingAnchor" id="H1624954252"><span class="h3">Imaging</span><span class="headingEndMark"> — </span>Chest radiographs are not routinely necessary for children who are admitted to the hospital with acute asthma exacerbations [<a href="#rid17">17</a>]. However, they may be warranted in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute worsening of clinical status (to look for potential complications of asthma: pneumothorax, pneumomediastinum, and pneumonia). Signs of such complications include fever ≥38.5ºC, focal examination findings (eg, crackles or decreased aeration), chest pain, unilateral absence of breath sounds, and/or extreme tachypnea or tachycardia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of response to asthma therapy (to look for other processes that can mimic asthma, such as vascular ring, inducible laryngeal obstruction [<a href="#rid23">23</a>], foreign body aspiration)  (<a class="graphic graphic_table graphicRef67370" href="/d/graphic/67370.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/5757.html" rel="external">"Vascular rings and slings"</a> and  <a class="medical medical_review" href="/d/html/6382.html" rel="external">"Airway foreign bodies in children"</a> and  <a class="medical medical_review" href="/d/html/5752.html" rel="external">"Evaluation of wheezing in infants and children"</a> and  <a class="medical medical_review" href="/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a>.)</p><p></p><p class="headingAnchor" id="H1248228024"><span class="h3">Laboratory studies</span><span class="headingEndMark"> — </span>Routine laboratories are not necessary for children who are hospitalized for acute asthma exacerbation and receiving intermittent inhalation therapy. Children receiving continuous <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> nebulization are at risk of transient hypokalemia, hypophosphatemia, and hypomagnesemia. Although these decreases are rarely of clinical importance in children, we typically measure serum electrolytes daily in patients receiving continuous albuterol, particularly those who have been taking diuretics regularly, have coexistent cardiovascular disease, and/or have a known predilection to electrolyte disturbances. (See  <a class="medical medical_review" href="/d/html/2341.html" rel="external">"Causes of hypokalemia in adults", section on 'Elevated beta-adrenergic activity'</a> and  <a class="medical medical_review" href="/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"</a>.)</p><p>Hypocarbia and respiratory alkalosis are frequently seen initially in children with asthma exacerbations due to an increased respiratory rate. Carbon dioxide (CO<sub>2</sub>) retention occurs only at extreme degrees of obstruction and has been found in people with near-fatal asthma [<a href="#rid24">24</a>]. A venous or capillary blood gas is useful in patients with asthma exacerbations and may be particularly helpful in patients who also have underlying lung disease (eg, bronchopulmonary dysplasia, cystic fibrosis, obstructive sleep apnea) and are on supplemental oxygen since these patients are at higher risk for hypercarbia. An arterial blood gas is indicated in patients with signs of impending respiratory failure. A normal or rising CO<sub>2</sub> level in a patient with tachypnea and respiratory distress is a concerning finding that suggests impending respiratory failure. Hypercarbia (PCO<sub>2</sub> ≥45 mmHg) despite maximal medical therapy is an indication for intubation and mechanical ventilation [<a href="#rid5">5</a>]. (See <a class="local">'Management of bronchospasm'</a> below and <a class="local">'Signs of impending respiratory failure'</a> above and  <a class="medical medical_review" href="/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H1749617848"><span class="h1">INITIAL THERAPY</span><span class="headingEndMark"> — </span>We recommend that children who are admitted to the hospital with an acute asthma exacerbation receive therapy with inhaled short-acting beta agonists (SABAs; eg, <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a>/salbutamol) [<a href="#rid25">25</a>]. The frequency of dosing depends upon the severity of the exacerbation and the patient's response to treatment. Children with moderate exacerbations usually require inhaled SABAs every one to three hours. In addition to the regularly scheduled beta agonist treatment, "as needed" treatments should be available for episodes of acute bronchospasm or worsening respiratory distress. Treatments are typically switched to continuous nebulized therapy if patients require treatment more often than every two hours. (See <a class="local">'Clinical assessment'</a> above and  <a class="medical medical_review" href="/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Asthma severity scores'</a>.)</p><p>We also recommend systemic glucocorticoids for children with acute asthma exacerbation who require hospitalization. Oral forms (eg, <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a>/<a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> or <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a>) are preferred over intramuscular or intravenous forms. Most children will have received their first dose in the acute care setting. (See <a class="local">'Management of inflammation'</a> below and  <a class="medical medical_review" href="/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Systemic glucocorticoids'</a>.)</p><p>Humidified oxygen should be provided as needed to maintain an oxygen saturation of ≥92 percent. (See <a class="local">'Management of hypoxemia'</a> below.)</p><p class="headingAnchor" id="H696426392"><span class="h1">THERAPY ADJUSTMENT</span><span class="headingEndMark"> — </span>Patients who do not improve or who clinically worsen need more frequent or additional treatments. Patients who are stable but not significantly improved should continue on the same frequency of treatments. Patients with clear improvement in clinical parameters should have the interval between their treatments increased. Titrating supplemental oxygen delivery is reviewed below. (See <a class="local">'Clinical assessment'</a> above and <a class="local">'Management of hypoxemia'</a> below.)</p><p>Some institutions have established multidisciplinary protocols (clinical pathways or care paths) for increasing or decreasing the frequency of inhaled short-acting beta agonist (SABA) treatments based upon asthma scores or other methods of assessment performed largely by respiratory therapists and/or nurses [<a href="#rid4">4,26,27</a>]. One example of a protocol that uses an asthma score is the modified Pediatric Respiratory Assessment Measure (PRAM)  (<a class="graphic graphic_table graphicRef91732" href="/d/graphic/91732.html" rel="external">table 4</a>) [<a href="#rid28">28</a>]. Another score used is the Pulmonary Index Score (PIS)  (<a class="graphic graphic_table graphicRef53797" href="/d/graphic/53797.html" rel="external">table 5</a>) [<a href="#rid29">29</a>]. The effect of such protocols was evaluated in a systematic review, which found that the use of clinical pathways appeared to be effective in reducing length of stay and hospital costs associated with pediatric asthma [<a href="#rid5">5,30</a>]. However, they were less effective in reducing readmission rates or affecting clinical outcomes, such as increasing asthma education and the use of controller medications or spacers [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2765717084"><span class="h2">Escalation of therapy</span><span class="headingEndMark"> — </span>In children admitted to the hospital with an asthma exacerbation, we switch from intermittent inhaled beta agonist treatments to continuous nebulized therapy if there is minimal to no improvement after several intermittent treatments and/or treatments are required more frequently than every two hours. Some hospitals only permit continuous administration in the intensive care unit (ICU). Patients treated with continuous therapy who do not improve rapidly should be monitored closely for worsening respiratory status. Delivery systems are discussed separately. (See <a class="local">'Initial assessment and ongoing monitoring'</a> above and  <a class="medical medical_review" href="/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"</a>.)</p><p class="headingAnchor" id="H2497524488"><span class="h3">Failure to respond</span><span class="headingEndMark"> — </span>Some patients fail to improve or worsen despite frequent or continuous administration of inhaled SABAs and systemic glucocorticoids. Reasons for worsening or failure to improve include severe asthma, development of a complication (eg, atelectasis, pneumothorax, pneumomediastinum, pneumonia), or incorrect diagnosis (ie, the patient's symptoms are caused by a process other than asthma)  (<a class="graphic graphic_table graphicRef67370" href="/d/graphic/67370.html" rel="external">table 3</a>). Obtaining a chest radiograph is warranted in these patients. Findings on chest radiographs and/or on lung examination (eg, crackles or localized decreased breath sounds with pneumonia or diminished breath sounds, hyperresonant percussion, and decreased vocal fremitus on the affected side in the case of a pneumothorax) can help to distinguish among these possibilities. Consultation with an asthma specialist may also help determine the underlying cause of the patient's worsening status or lack of improvement. (See  <a class="medical medical_review" href="/d/html/6340.html" rel="external">"Spontaneous pneumothorax in children", section on 'Physical examination'</a> and <a class="local">'Imaging'</a> above and  <a class="medical medical_review" href="/d/html/5752.html" rel="external">"Evaluation of wheezing in infants and children"</a> and  <a class="medical medical_review" href="/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'History and examination'</a> and <a class="local">'Asthma specialist'</a> below.)</p><p class="headingAnchor" id="H1651169785"><span class="h3">Indications for PICU/anesthesia consult</span><span class="headingEndMark"> — </span>A pediatric intensive care unit (PICU) and/or anesthesia consult should be obtained for children receiving continuous nebulized <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> therapy who have increasing fatigue, increasing work of breathing, CO<sub>2</sub> retention, or worsening hypoxemia. These children are at risk for further decompensation and may need noninvasive ventilation or intubation. Most will need to be transferred to the PICU for closer monitoring and more aggressive treatment. (See <a class="local">'Signs of impending respiratory failure'</a> above and  <a class="medical medical_review" href="/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"</a>.)</p><p class="headingAnchor" id="H3873707731"><span class="h2">Weaning of therapy</span><span class="headingEndMark"> — </span>Children receiving continuous nebulized <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> are switched to intermittent therapy given every two to three hours when they have improving asthma parameters or score. Weaning or spacing out therapies is performed when indications of clinical improvement are present based upon close monitoring of symptoms and vital signs. Standardized Clinical Assessment and Management Plans (SCAMPs) and other such pathways have been used to more quickly wean patients off of continuous nebulized therapy [<a href="#rid31">31,32</a>]. (See <a class="local">'Clinical assessment'</a> above and  <a class="medical medical_review" href="/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Assessment of exacerbation severity'</a> and  <a class="medical medical_review" href="/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Asthma severity scores'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">ELEMENTS OF TREATMENT</span><span class="headingEndMark"> — </span>Asthma treatment includes inhaled short-acting beta agonists (SABAs or beta agonists)  (<a class="graphic graphic_table graphicRef134102" href="/d/graphic/134102.html" rel="external">table 6</a>), systemic glucocorticoids (such as <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a>/<a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> or <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a>)  (<a class="graphic graphic_table graphicRef53629" href="/d/graphic/53629.html" rel="external">table 7</a>), and supplemental oxygen when needed. Our approach is consistent with expert guidelines [<a href="#rid5">5,33,34</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Management of bronchospasm</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled SABAs</strong> – SABAs (eg, <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a>/salbutamol) are one of the primary therapies for acute asthma exacerbations. (See  <a class="medical medical_review" href="/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing and administration </strong>– The National Asthma Education and Prevention Program (NAEPP) has published doses for common medications used during asthma exacerbation [<a href="#rid5">5</a>]. However, weight-based dosing of inhaled SABAs may not be appropriate for young children, because of the low deposition of medication in the lungs [<a href="#rid4">4,35</a>]. Standard doses, such as 2.5 mg of nebulized <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> for children who weigh less than 30 kg and 5 mg for children who weigh more than 30 kg, may be used [<a href="#rid4">4</a>]. Common metered-dose inhaler (MDI) doses for albuterol in children range from four to eight puffs, although typically the dose does not exceed six puffs.</p><p></p><p class="bulletIndent2">SABAs are administered continuously (via nebulizer) or intermittently (via MDI with valved holding chamber/spacer or nebulizer) [<a href="#rid18">18,35-41</a>]. All nebulized treatments should be given with oxygen (usually 100 percent fraction of inspired oxygen [FiO<sub>2</sub>]) as the driving gas rather than with compressed air since most patients admitted for an asthma exacerbation will have some degree of hypoxemia. A flow rate of 6 to 8 L/min produces the optimal particle size for airway deposition.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – Data in adults indicate that continuous nebulized <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> is as efficacious as intermittent nebulization [<a href="#rid41">41,42</a>]. Continuous nebulized albuterol also appears to be safe and effective in children [<a href="#rid18">18,37-40,43,44</a>]. In one small, randomized trial, children with severe status asthmaticus on continuous albuterol improved more rapidly and no longer had impending respiratory failure within a median of 12 hours (range 4 to 24) compared with 18 hours (range 12 to 24) in the intermittent albuterol group [<a href="#rid39">39</a>]. Results from another small, randomized trial suggest that continuous nebulization of <a class="drug drug_pediatric" data-topicid="12546" href="/d/drug information/12546.html" rel="external">levalbuterol</a> (levosalbutamol), which consists of only the R-enantiomer of albuterol [<a href="#rid45">45,46</a>], is no more effective than albuterol, which is a racemic mixture of the R- and S-enantiomers [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Levalbuterol'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse effects </strong>– Potential adverse effects of beta-agonist therapy include transient decreases in serum potassium, magnesium, and phosphate [<a href="#rid5">5</a>]. These decreases are rarely of clinical importance in children. Other adverse effects include an increased heart rate and decreased diastolic blood pressure and mean arterial pressure, which were seen during nebulization compared with measurements at initiation of therapy or at hospital discharge in one study [<a href="#rid49">49</a>]. (See <a class="local">'Laboratory studies'</a> above and  <a class="medical medical_review" href="/d/html/2341.html" rel="external">"Causes of hypokalemia in adults", section on 'Elevated beta-adrenergic activity'</a> and  <a class="medical medical_review" href="/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults"</a>.)</p><p></p><p class="bulletIndent2">The three most common adverse drug events (ADEs) associated with intermittent SABAs are anxiety (range 0 to 52 percent, <a class="drug drug_pediatric" data-topicid="12546" href="/d/drug information/12546.html" rel="external">levalbuterol</a>), tachycardia (range 13.6 to 14 percent, salbutamol), and supraventricular ectopy (range 0 to 14 percent, salbutamol) [<a href="#rid50">50</a>]. With continuous SABAs, 50 percent of ADEs affected the cardiovascular system, with the three most common ADEs being tachycardia (range 94 to 95 percent, salbutamol), diastolic hypotension (range 66 to 98 percent, salbutamol), and lactic acidosis (80.6 percent, salbutamol).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other bronchodilators – </strong>Other bronchodilators (eg, <a class="drug drug_pediatric" data-topicid="13389" href="/d/drug information/13389.html" rel="external">ipratropium</a> bromide, <a class="drug drug_pediatric" data-topicid="12982" href="/d/drug information/12982.html" rel="external">magnesium sulfate</a>, <a class="drug drug_pediatric" data-topicid="12826" href="/d/drug information/12826.html" rel="external">terbutaline</a>, <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>) are used in the emergency department (ED) or intensive care unit (ICU) settings, but not routinely in the regular inpatient unit, and are discussed separately. (See  <a class="medical medical_review" href="/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Management of bronchospasm'</a> and  <a class="medical medical_review" href="/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management", section on 'Bronchodilators'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Management of inflammation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids </strong>– Systemic glucocorticoids are an important component of the management of asthma exacerbations due to their ability to decrease airway inflammation and secretions by reducing the production of inflammatory mediators, capillary permeability, and the activity of lymphocytes [<a href="#rid51">51</a>]. In acute severe asthma, the administration of glucocorticoids also enhances the bronchodilator response to beta agonists by reversing desensitization and downregulation of beta receptors [<a href="#rid52">52</a>]. In the rare cases in which glucocorticoids are contraindicated (eg, hypersensitivity reaction, varicella infection, herpes simplex keratitis), the severity of bronchospasm must be weighed against the reason for the contraindication.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing and administration </strong>–<strong> </strong>Glucocorticoids may be given as <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a>, <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a>, <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a>, or <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a>, all of which have been shown to decrease inflammation in asthma [<a href="#rid53">53</a>]. They are similar in how well and how quickly (one to two hours after an enteral dose) they decrease asthma symptoms. The plasma half-life, which correlates with the antiinflammatory potency of glucocorticoids, is longer for dexamethasone than either prednisone or prednisolone  (<a class="graphic graphic_table graphicRef64138" href="/d/graphic/64138.html" rel="external">table 8</a>). Dosing varies from institution to institution but is typically 2 mg/kg/day of prednisone, prednisolone, or methylprednisolone orally in divided doses given twice daily for a total of five days (with a maximum dose of 60 mg per day) [<a href="#rid5">5</a>]. An alternative is to administer as a single dose given once daily. Dexamethasone dosing is typically 0.3 to 0.6 mg/kg (maximum daily dose of 8 to 16 mg), given as a single daily oral dose, a twice-daily split oral dose, or a single daily intramuscular dose for a total of two days. (See  <a class="medical medical_review" href="/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Systemic glucocorticoids'</a> and  <a class="medical medical_review" href="/d/html/124.html" rel="external">"Pharmacologic use of glucocorticoids"</a>.)</p><p></p><p class="bulletIndent2">Oral administration is preferred to intravenous administration since it is less invasive and equally efficacious [<a href="#rid5">5,54</a>]. Glucocorticoids can be given intravenously, or intramuscularly in the case of <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a>, if the patient cannot tolerate oral administration (eg, due to gastrointestinal impairment or repeated spitting or vomiting of doses).</p><p></p><p class="bulletIndent2">Clinical experience suggests a longer course (eg, 7 to 10 days) may be beneficial for patients who have a severe exacerbation that is slow to respond to treatment or patients who have had more than one exacerbation requiring oral glucocorticoids in the previous two months. In addition, patients whose control regimen includes oral glucocorticoids may benefit from a &gt;10 day course.</p><p></p><p class="bulletIndent2">We taper systemic glucocorticoid therapy in patients who require a course longer than 14 to 21 days [<a href="#rid5">5</a>]. Glucocorticoid therapy may be tapered in a number of ways. We typically decrease the dose by 50 percent every two to three days (ie, 2 mg/kg/day for days 1 to 10, 1 mg/kg/day for days 11 to 12, 0.5 mg/kg/day for days 13 to 14, and 0.25 mg/kg/day for days 15 to 16). A more gradual taper may be indicated for patients receiving chronic oral glucocorticoid therapy. (See  <a class="medical medical_review" href="/d/html/7983.html" rel="external">"Glucocorticoid withdrawal"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – Studies of ED management of acute asthma exacerbations in children suggest that a two-day course of oral <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> is as effective as a five-day course of oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> with regard to return visits to the ED, hospital admission or readmission, and persistence of symptoms and has fewer side effects [<a href="#rid55">55,56</a>]. There are no studies that have examined the use of dexamethasone in the inpatient setting, although it is used in some centers [<a href="#rid53">53,57</a>]. A systematic review of oral glucocorticoids for acute asthma exacerbations in adults and children found no difference in outcomes between <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> and dexamethasone [<a href="#rid58">58</a>], nor between shorter and longer courses or lower or higher doses of systemic glucocorticoids. However, meta-analyses were limited by the heterogeneity among interventions and outcomes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse effects</strong> – Glucocorticoids have adverse effects on many organ systems  (<a class="graphic graphic_table graphicRef65998" href="/d/graphic/65998.html" rel="external">table 9</a>) [<a href="#rid50">50</a>]. Even short-term use of oral glucocorticoids can result in transient adrenal suppression, an effect that appears to be dose related. Adrenal suppression following treatment with <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> has not been well studied. The adverse effects of glucocorticoids are dose and duration dependent and are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled glucocorticoids </strong>– Inhaled glucocorticoids are not as effective as systemic glucocorticoids for severe asthma exacerbations and should not be used as a substitute for systemic glucocorticoids [<a href="#rid5">5,59-61</a>]. However, previous home treatment with inhaled glucocorticoids is typically continued during an admission while the patient is on systemic glucocorticoids. It is also not necessary to wait until a patient has completed a course of systemic glucocorticoids before starting inhaled glucocorticoids. The additional effects of inhaled glucocorticoids while on systemic glucocorticoids are insignificant, but the hope is that use during the admission will promote adherence to outpatient therapy after discharge. This also allows for review of administration technique and correction of any errors. (See <a class="local">'Discharge medications'</a> below.)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Management of hypoxemia</span><span class="headingEndMark"> — </span>Patients with acute asthma have ventilation-perfusion (V/Q) mismatch, which may lead to hypoxemia. Beta agonists may worsen this mismatch by causing increased blood flow in areas of the lung that are poorly ventilated. Oxyhemoglobin saturation may decrease by ≥5 percent in the first 30 minutes after an <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> treatment [<a href="#rid62">62</a>].</p><p>Supplemental oxygen (humidified) should be provided by nasal cannula or facemask as needed to maintain an oxygen saturation of ≥92 percent [<a href="#rid63">63</a>]. All nebulized medications should be delivered with oxygen, generally at a flow rate of 6 to 8 L/min. Small children should be placed on infant flow meters to allow accurate weaning below 1 L/min of flow. (See  <a class="medical medical_review" href="/d/html/6394.html" rel="external">"Continuous oxygen delivery systems for the acute care of infants, children, and adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Titration of supplemental oxygen </strong>– We typically adjust the oxygen flow rate as follows, depending upon the oxygen saturation [<a href="#rid4">4</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥94 percent – Decrease the flow rate by one-quarter L/minute for children who weigh &lt;15 kg and by one-half L/minute for children who weigh ≥15 kg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>91 to 94 percent – Continue the same flow rate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≤90 percent – Increase the flow rate to achieve a saturation of 91 to 94 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Patients receiving supplemental oxygen therapy should be monitored with continuous pulse oximetry [<a href="#rid4">4</a>]. Oxygen saturation should be noted at the time of each patient assessment by the nurse, respiratory therapist, or clinician. Oxygen saturation should be rechecked 5 to 10 minutes after changes to the oxygen flow rate. The oxygen flow rate can continue to be decreased further if the patient's oxygen saturation remains ≥94 percent each time it is rechecked. Changes to the oxygen flow rate should be documented appropriately. (See <a class="local">'Initial assessment and ongoing monitoring'</a> above.)</p><p></p><p class="bulletIndent1">Once patients are no longer receiving supplemental oxygen therapy, oximetry should be monitored 5 to 10 minutes after discontinuation, just before the next inhaled beta-agonist treatment, and while the child is sleeping for the first sleep period after discontinuation [<a href="#rid4">4</a>]. Pulse oximetry can be discontinued if the oxygen saturation remains ≥92 percent for each of these situations.</p><p></p><p class="bulletIndent1">Children with underlying lung disease (eg, bronchopulmonary dysplasia, cystic fibrosis, obstructive sleep apnea) should also be monitored closely for hypercarbia while receiving supplemental oxygen. (See <a class="local">'Laboratory studies'</a> above.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Therapies reserved for special circumstances</span></p><p class="headingAnchor" id="H201991475"><span class="h3">ICU care</span><span class="headingEndMark"> — </span>Inpatient use of systemic beta agonists, methylxanthines, and <a class="drug drug_pediatric" data-topicid="12982" href="/d/drug information/12982.html" rel="external">magnesium sulfate</a> is reserved for patients with severe exacerbations who are admitted to the intensive care unit (ICU) since use of these medications requires a higher level of monitoring than is available on regular nursing units. Other therapies used in the ICU include noninvasive positive pressure ventilation and high-flow nasal cannula. These therapies are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Comorbid infection</span><span class="headingEndMark"> — </span>Routine antibiotic administration has no benefit in acute asthma exacerbations [<a href="#rid64">64,65</a>]. However, antibiotics may be indicated to treat comorbid infections (eg, bacterial pneumonia, bacterial sinusitis) [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment", section on 'Empiric therapy'</a> and  <a class="medical medical_review" href="/d/html/5999.html" rel="external">"Acute bacterial rhinosinusitis in children: Microbiology and management", section on 'Empiric antibiotics'</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Atelectasis</span><span class="headingEndMark"> — </span>Chest physiotherapy is not recommended for routine inpatient treatment of asthma exacerbations. It is not beneficial and may subject the patient to unnecessary stress [<a href="#rid5">5,67-69</a>]. An exception may be made for children with asthma exacerbation complicated by atelectasis. (See  <a class="medical medical_review" href="/d/html/6378.html" rel="external">"Atelectasis in children"</a>.)</p><p class="headingAnchor" id="H303053595"><span class="h2">Therapies not used in the inpatient setting</span><span class="headingEndMark"> — </span>Inhaled <a class="drug drug_pediatric" data-topicid="13389" href="/d/drug information/13389.html" rel="external">ipratropium</a> bromide and oral leukotriene receptor antagonists (LTRAs) are not used as adjunctive therapy for hospitalized patients.</p><p class="headingAnchor" id="H1009248670"><span class="h3">Ipratropium bromide</span><span class="headingEndMark"> — </span>Although the addition of inhaled <a class="drug drug_pediatric" data-topicid="13389" href="/d/drug information/13389.html" rel="external">ipratropium</a> bromide to inhaled beta-agonist therapy has proven effective in the ED setting, studies of its use during hospital admissions have not revealed added benefit [<a href="#rid70">70-73</a>]. Thus, ipratropium bromide is not used as standard therapy during hospitalizations for asthma exacerbations.</p><p class="headingAnchor" id="H3851736304"><span class="h3">Leukotriene receptor antagonists</span><span class="headingEndMark"> — </span>There are no data on the use of LTRAs (eg, <a class="drug drug_pediatric" data-topicid="12620" href="/d/drug information/12620.html" rel="external">montelukast</a>, <a class="drug drug_pediatric" data-topicid="12887" href="/d/drug information/12887.html" rel="external">zafirlukast</a>) for acute asthma exacerbations in children in the hospital setting. Patients taking an LTRA for long-term asthma control do not need to continue it while receiving systemic glucocorticoids during hospitalization for an acute asthma exacerbation. LTRAs should be restarted at the time of discharge if the plan is to continue them. (See  <a class="medical medical_review" href="/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma", section on 'Clinical use of leukotriene-modifying drugs in asthma'</a> and  <a class="medical medical_review" href="/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">CONSULTATION</span></p><p class="headingAnchor" id="H34"><span class="h2">Asthma specialist</span><span class="headingEndMark"> — </span>Many children with asthma respond quickly to standard care. The inpatient management of such patients need not involve an asthma specialist (eg, pediatric pulmonologist or pediatric allergist). However, consultation with an asthma specialist may be warranted in the following circumstances [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis is in question or the patient fails to improve. (See <a class="local">'Failure to respond'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening asthma exacerbation, including any patient requiring intensive care management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeated hospital admission, history of intensive care unit (ICU) admission, frequent emergency department (ED) visits, or need for multiple or frequent drug therapies at home.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions complicating asthma (eg, sinusitis, nasal polyps, chronic lung disease of prematurity, allergic bronchopulmonary aspergillosis, gastroesophageal reflux, obesity, food allergy, etc).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with asthma and other chronic disease (eg, cystic fibrosis, restrictive lung disease, neuromuscular weakness).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient requires extensive education about allergen avoidance, problems with adherence to therapy, or complications of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient is receiving or would benefit from establishing ongoing care by an asthma specialist (ie, those with severe or difficult-to-treat asthma).</p><p></p><p>Long-term follow-up with an asthma specialist may be warranted for some patients, particularly those who had near-fatal asthma or required ICU care [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/547.html" rel="external">"An overview of asthma management", section on 'When to refer'</a>.)</p><p class="headingAnchor" id="H35"><span class="h2">Social services</span><span class="headingEndMark"> — </span>Consultation with social services may be warranted when caregiver resources are inadequate to ensure medication availability, adherence, and/or medical follow-up and to help caregivers connect with asthma programs available in the community [<a href="#rid17">17</a>]. Social services also may be helpful when environmental triggers related to housing play a role in the asthma exacerbation (eg, rodents, cockroaches, smoke exposure). (See  <a class="medical medical_review" href="/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a>.)</p><p class="headingAnchor" id="H3797778323"><span class="h1">DISCHARGE PLANNING</span><span class="headingEndMark"> — </span>Planning for discharge begins at the time of admission. The patient's and caregiver's understanding of asthma, including signs and symptoms, triggers, medications, and self-monitoring, should be assessed so that appropriate education can be provided [<a href="#rid5">5</a>]. For patients newly diagnosed with asthma, it is important to anticipate the need for medication equipment, such as a spacer (preferably a valved holding chamber) or a nebulizer with compressor, so that it can be delivered to the caregiver and they can learn how to use it before the child is discharged. (See <a class="local">'Discharge medications'</a> below.)</p><p class="headingAnchor" id="H36"><span class="h2">Discharge criteria</span><span class="headingEndMark"> — </span>Specific criteria for discharge vary from institution to institution. General principles to determine appropriate discharge may be used. Patients may be discharged when:</p><p class="bulletIndent1"><span class="glyph">●</span>Their asthma symptoms and signs (and scores, if available) are considered mild. Standardized tools, such as the Pediatric Dyspnea Scale (PDS)  (<a class="graphic graphic_figure graphicRef80389" href="/d/graphic/80389.html" rel="external">figure 1</a>), may be useful. In one study, the PDS predicted poor outcomes after discharge, including relapse and activity limitation, and was a better indicator than measures of pulmonary function [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>They no longer require supplemental oxygen (peripheral arterial oxygen saturation [SpO<sub>2</sub>] ≥94 percent without supplemental oxygen).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>They are receiving a treatment regimen that can be reasonably duplicated at home (eg, they are tolerating oral medications, and the frequency and proper technique of inhalation treatments can be managed by the caregiver, usually every four to six hours). If possible, patients should be observed in the hospital for at least one interval while receiving the treatments that will be prescribed after discharge. If patients have been receiving nebulized medications, they may be changed to metered-dose inhaler (MDI) spacer after continuous therapy is no longer needed or any time prior to discharge provided they can demonstrate proper technique.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Access to medications and appropriate follow-up have been confirmed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asthma education is complete. (See <a class="local">'Discharge education'</a> below.)</p><p></p><p class="headingAnchor" id="H37"><span class="h2">Discharge medications</span><span class="headingEndMark"> — </span>Hospitalization for an asthma exacerbation signifies a break in control. The patient's preadmission medication regimen, asthma severity classification, and asthma control should be reviewed and controller medications adjusted as indicated  (<a class="graphic graphic_table graphicRef80908 graphicRef71181" href="/d/graphic/80908.html" rel="external">table 10A-B</a> and <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/d/graphic/127785.html" rel="external">table 1A-B</a> and <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/d/graphic/78322.html" rel="external">table 11A-B</a>).</p><p>Discharge medications should include an inhaled short-acting beta agonist (SABA), either via nebulizer or MDI with a valved holding chamber/spacer, and oral glucocorticoids if the course was not already completed during the hospitalization [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The beta agonist should be continued roughly every four to six hours until the patient is seen in follow-up within three to five days. Frequency can then be decreased or returned to "as needed" depending upon the rate of clinical improvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral glucocorticoids are usually continued for a total of five days, although a two-day course of <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> may be sufficient. Indications for longer courses are discussed above. (See <a class="local">'Management of inflammation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The need for daily controller therapy should be reviewed prior to discharge. Step-up therapy is often indicated in patients who were already on controller medication prior to the admission. Daily controller therapy, at least for a few months, is indicated for almost all children who have been hospitalized with an asthma exacerbation. Controller medications and preferred regimens are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5744.html" rel="external">"Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"</a>.)</p><p></p><p>The patient should have all maintenance medications and the equipment necessary for their delivery (eg, valved holding chamber/spacer, mask, nebulizer, nebulizer tubing and mask, etc) prior to discharge. One way of assuring this is to have the caregiver fill the prescriptions before discharge. An advantage of this approach is that it permits the inpatient team to review the proper technique for medication administration. If the caregiver is unable to fill the prescriptions before discharge, patient demonstrator devices may be used to review technique. (See <a class="local">'Discharge education'</a> below and  <a class="medical medical_review" href="/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a> and  <a class="medical medical_review" href="/d/html/5736.html" rel="external">"Use of medication nebulizers in children"</a>.)</p><p class="headingAnchor" id="H38"><span class="h2">Discharge education</span><span class="headingEndMark"> — </span>The inpatient hospitalization is an excellent time to provide education about asthma. Every interaction should be viewed as an opportunity to educate the patient and caregiver(s).</p><p>The various aspects of asthma education can be provided by any member of the health care team with adequate training. Some institutions have dedicated asthma educators that assist with the education process. (See  <a class="medical medical_review" href="/d/html/547.html" rel="external">"An overview of asthma management", section on 'Patient education'</a>.)</p><p>Areas of asthma education that should be covered include:</p><p class="bulletIndent1"><span class="glyph">●</span>The importance of taking medications properly and consistently. How each medication works should also be discussed, including the difference between daily long-term controller medications and quick-relief rescue medications. (See  <a class="medical medical_review" href="/d/html/5744.html" rel="external">"Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"</a> and  <a class="medical medical_review" href="/d/html/5743.html" rel="external">"Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The proper technique of medication administration, which can be demonstrated throughout the hospitalization. (See  <a class="medical medical_review" href="/d/html/5736.html" rel="external">"Use of medication nebulizers in children"</a> and  <a class="medical medical_review" href="/d/html/5738.html" rel="external">"The use of inhaler devices in children", section on 'pMDI technique'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring asthma symptoms and identifying and avoiding triggers when possible, including avoidance of irritants (eg, tobacco smoke) and allergens (when relevant) and ensuring that the child receives the yearly influenza vaccine  (<a class="graphic graphic_table graphicRef72029" href="/d/graphic/72029.html" rel="external">table 12</a>). (See  <a class="medical medical_review" href="/d/html/566.html" rel="external">"Asthma education and self-management"</a> and  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'</a>.)</p><p></p><p class="headingAnchor" id="H39"><span class="h2">Asthma action plan</span><span class="headingEndMark"> — </span>Patients should be given a written asthma action plan that includes [<a href="#rid5">5,75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A list of the daily medications and the time(s) of day they are to be taken</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A list of the quick-relief medication(s) and a description of the symptoms for which they should be taken</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The phone number they should call if they have questions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A list of triggers that may exacerbate their asthma (see  <a class="medical medical_review" href="/d/html/562.html" rel="external">"Trigger control to enhance asthma management"</a> and  <a class="medical medical_review" href="/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a>)</p><p></p><p>The National Asthma Education and Prevention Program (NAEPP) provides sample asthma action plans for children aged zero to five years  (<a class="graphic graphic_form graphicRef71958" href="/d/graphic/71958.html" rel="external">form 1</a>), patients older than five years  (<a class="graphic graphic_form graphicRef55900" href="/d/graphic/55900.html" rel="external">form 2</a>), and for use at school <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsecure.aafa.org%2Fnp%2Fclients%2Faafa%2Fproduct.jsp%3Fproduct%3D11%26&amp;token=8m4J%2Bg%2BXcXj7fA1pdpQ5R6qG2OXn%2BGQ%2FfdbnyvzenHzpw5di5sLg88Q6aZ%2FsflPxmTMKcP8qHzIzaj1XpZ0bAQ%3D%3D&amp;TOPIC_ID=5748" target="_blank">(Student Asthma Action Card)</a>.</p><p class="headingAnchor" id="H18852727"><span class="h2">Care coordination/case management</span><span class="headingEndMark"> — </span>Care coordination and case management, both during the hospitalization and after discharge, are particularly important in patients who have had repeated admissions for asthma exacerbations. Maintaining the continuity of care is important, as is reinforcing the asthma education received during the hospitalization. (See <a class="local">'Discharge education'</a> above.)</p><p class="headingAnchor" id="H40"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Patients discharged from the hospital should have follow-up in three to five days with their primary care provider or asthma specialist [<a href="#rid5">5</a>]. At the follow-up visit, the primary care provider can review the child's severity/control classification, alter controller therapy as indicated, and taper or discontinue inhaled SABA therapy  (<a class="graphic graphic_table graphicRef80908 graphicRef71181" href="/d/graphic/80908.html" rel="external">table 10A-B</a> and <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/d/graphic/127785.html" rel="external">table 1A-B</a> and <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/d/graphic/78322.html" rel="external">table 11A-B</a>). (See  <a class="medical medical_review" href="/d/html/5744.html" rel="external">"Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"</a> and <a class="local">'Asthma specialist'</a> above.)</p><p>The clinician monitoring the child's asthma should ascertain whether the patient's asthma medications are available and whether they are properly used (including associated devices). Patients should be reminded to refill their prescriptions as indicated and make certain the ones they have are not expired or depleted.</p><p class="headingAnchor" id="H3908233374"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113453.html" rel="external">"Society guideline links: Asthma in children"</a>.)</p><p class="headingAnchor" id="H41"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – Inpatient treatment typically is a continuation of therapies and monitoring that were started in the emergency department (ED). (See <a class="local">'Overview'</a> above and <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of bronchospasm</strong> – All children who are admitted to the hospital with an acute asthma exacerbation require treatment with an inhaled short-acting beta agonist (SABA or beta agonist), such as <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> (salbutamol) or an equivalent. The frequency of administration ranges anywhere from continuously to every four hours, depending upon the severity of the exacerbation and the patient's response to treatment. (See <a class="local">'Management of bronchospasm'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of inflammation</strong> – We recommend that children who are admitted to the hospital with an acute asthma exacerbation be treated with systemic glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Management of inflammation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of hypoxemia</strong> – Humidified oxygen should be provided as needed to maintain an oxygen saturation of ≥92 percent. (See <a class="local">'Management of hypoxemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical assessment and frequency of monitoring</strong> – Clinical status and response to therapy must be monitored frequently during treatment for acute asthma exacerbation  (<a class="graphic graphic_table graphicRef76344" href="/d/graphic/76344.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef91732" href="/d/graphic/91732.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef53797" href="/d/graphic/53797.html" rel="external">table 5</a>). Patients are typically assessed every 15 minutes to every four hours, depending upon the clinical status. (See <a class="local">'Initial assessment and ongoing monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to obtain imaging</strong> – Chest radiographs are not routinely necessary for children who are admitted to the hospital with acute asthma exacerbations. However, they may be warranted in patients with acute worsening of clinical status or lack of response to asthma therapy. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Escalation of therapy</strong> – Failure to respond to standard asthma therapy may indicate impending respiratory failure, development of a complication, or a disease process other than asthma  (<a class="graphic graphic_table graphicRef67370" href="/d/graphic/67370.html" rel="external">table 3</a>). Such patients may require transfer to the intensive care unit (ICU). Signs of impending respiratory failure include (see <a class="local">'Failure to respond'</a> above and <a class="local">'Signs of impending respiratory failure'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced or inaudible breath sounds</p><p class="bulletIndent2"><span class="glyph">•</span>Worsening hypoxemia</p><p class="bulletIndent2"><span class="glyph">•</span>Fatigue</p><p class="bulletIndent2"><span class="glyph">•</span>Change in mental status</p><p class="bulletIndent2"><span class="glyph">•</span>CO<sub>2</sub> retention</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weaning of therapy</strong> – Children receiving continuous nebulized <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> are switched to intermittent therapy given every two to three hours when they have improving asthma parameters or score. Weaning or spacing out therapies is performed when indications of clinical improvement are present based upon close monitoring of symptoms and vital signs. (See <a class="local">'Weaning of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discharge criteria and follow-up</strong> – Discharge criteria include asthma signs and symptoms that are mild to absent, lack of requirement for supplemental oxygen, a treatment regimen that is suitable for home administration with availability of all medications and equipment, completion of asthma education to ensure that patients and care providers know how to properly administer medications and recognize symptoms, and a follow-up visit scheduled with the primary care provider or asthma specialist in three to five days. (See <a class="local">'Discharge criteria'</a> above and <a class="local">'Follow-up'</a> above.)</p><p></p><p class="headingAnchor" id="H1324521"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mark Dovey, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Centers for Disease Control and Prevenion (CDC). Most Recent National Asthma Data. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm (Accessed on August 28, 2023).</li><li class="breakAll">Healthcare Cost and Utilization Project (HCUPnet). Agency for Healthcare Research and Quality, US Department of Health &amp; Human Services. Rockville, MD. https://hcupnet.ahrq.gov/ (Accessed on October 04, 2019).</li><li class="breakAll">National Ambulatory Medical Survey (NAMCS). Centers for Disease Control and Prevention (CDC), National Center for Health Stastistics (NCHS). https://www.cdc.gov/nchs/ahcd/about_ahcd.htm (Accessed on October 04, 2019).</li><li class="breakAll">Asthma team CCHMC. Evidence based care guideline for managing an acute exacerbation of asthma. www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/asthma.htm (Accessed on February 08, 2008).</li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 08, 2008).</li><li><a class="nounderline abstract_t">Nkoy FL, Fassl BA, Simon TD, et al. Quality of care for children hospitalized with asthma. Pediatrics 2008; 122:1055.</a></li><li class="breakAll">Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. https://ginasthma.org/gina-reports/ (Accessed on October 01, 2020).</li><li><a class="nounderline abstract_t">Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev 2013; :CD000060.</a></li><li><a class="nounderline abstract_t">Wright RO, Santucci KA, Jay GD, Steele DW. Evaluation of pre- and posttreatment pulse oximetry in acute childhood asthma. Acad Emerg Med 1997; 4:114.</a></li><li><a class="nounderline abstract_t">Solé D, Komatsu MK, Carvalho KV, Naspitz CK. Pulse oximetry in the evaluation of the severity of acute asthma and/or wheezing in children. J Asthma 1999; 36:327.</a></li><li><a class="nounderline abstract_t">Gorelick MH, Stevens MW, Schultz T, Scribano PV. Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. Pediatr Emerg Care 2004; 20:22.</a></li><li><a class="nounderline abstract_t">Smith SR, Baty JD, Hodge D 3rd. Validation of the pulmonary score: an asthma severity score for children. Acad Emerg Med 2002; 9:99.</a></li><li><a class="nounderline abstract_t">Becker AB, Nelson NA, Simons FE. The pulmonary index. Assessment of a clinical score for asthma. Am J Dis Child 1984; 138:574.</a></li><li><a class="nounderline abstract_t">Carroll CL, Sekaran AK, Lerer TJ, Schramm CM. A modified pulmonary index score with predictive value for pediatric asthma exacerbations. Ann Allergy Asthma Immunol 2005; 94:355.</a></li><li><a class="nounderline abstract_t">Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993; 92:513.</a></li><li><a class="nounderline abstract_t">Smith SR, Strunk RC. Acute asthma in the pediatric emergency department. Pediatr Clin North Am 1999; 46:1145.</a></li><li class="breakAll">Asthma team CCHMC. Evidence based care guideline for managing an acute exacerbation of asthma. www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/asthma.htm (Accessed on February 09, 2008).</li><li><a class="nounderline abstract_t">Katz RW, Kelly HW, Crowley MR, et al. Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics 1993; 92:666.</a></li><li><a class="nounderline abstract_t">Shein SL, Speicher RH, Filho JO, et al. Contemporary treatment of children with critical and near-fatal asthma. Rev Bras Ter Intensiva 2016; 28:167.</a></li><li><a class="nounderline abstract_t">Stephanopoulos DE, Monge R, Schell KH, et al. Continuous intravenous terbutaline for pediatric status asthmaticus. Crit Care Med 1998; 26:1744.</a></li><li><a class="nounderline abstract_t">Matson JR, Loughlin GM, Strunk RC. Myocardial ischemia complicating the use of isoproterenol in asthmatic children. J Pediatr 1978; 92:776.</a></li><li><a class="nounderline abstract_t">Maguire JF, Geha RS, Umetsu DT. Myocardial specific creatine phosphokinase isoenzyme elevation in children with asthma treated with intravenous isoproterenol. J Allergy Clin Immunol 1986; 78:631.</a></li><li><a class="nounderline abstract_t">Denipah N, Dominguez CM, Kraai EP, et al. Acute Management of Paradoxical Vocal Fold Motion (Vocal Cord Dysfunction). Ann Emerg Med 2017; 69:18.</a></li><li><a class="nounderline abstract_t">McFadden ER Jr, Lyons HA. Arterial-blood gas tension in asthma. N Engl J Med 1968; 278:1027.</a></li><li><a class="nounderline abstract_t">Ben-Zvi Z, Lam C, Hoffman J, et al. An evaluation of the initial treatment of acute asthma. Pediatrics 1982; 70:348.</a></li><li><a class="nounderline abstract_t">Wazeka A, Valacer DJ, Cooper M, et al. Impact of a pediatric asthma clinical pathway on hospital cost and length of stay. Pediatr Pulmonol 2001; 32:211.</a></li><li><a class="nounderline abstract_t">Johnson KB, Blaisdell CJ, Walker A, Eggleston P. Effectiveness of a clinical pathway for inpatient asthma management. Pediatrics 2000; 106:1006.</a></li><li><a class="nounderline abstract_t">Ducharme FM, Chalut D, Plotnick L, et al. The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. J Pediatr 2008; 152:476.</a></li><li><a class="nounderline abstract_t">Sneller H, Carroll CL, Welch K, Sturm J. Differentiating non-responders from responders in children with moderate and severe asthma exacerbations. J Asthma 2020; 57:405.</a></li><li><a class="nounderline abstract_t">Banasiak NC, Meadows-Oliver M. Inpatient asthma clinical pathways for the pediatric patient: an integrative review of the literature. Pediatr Nurs 2004; 30:447.</a></li><li><a class="nounderline abstract_t">Wong J, Agus MS, Graham DA, Melendez E. A Critical Asthma Standardized Clinical and Management Plan Reduces Duration of Critical Asthma Therapy. Hosp Pediatr 2017; 7:79.</a></li><li><a class="nounderline abstract_t">Brennan S, Lowrie L, Wooldridge J. Effects of a PICU Status Asthmaticus De-Escalation Pathway on Length of Stay and Albuterol Use. Pediatr Crit Care Med 2018; 19:658.</a></li><li><a class="nounderline abstract_t">Lougheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respir J 2012; 19:127.</a></li><li class="breakAll">Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, updated 2019. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf.</li><li><a class="nounderline abstract_t">Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135:28.</a></li><li><a class="nounderline abstract_t">Mandelberg A, Tsehori S, Houri S, et al. Is nebulized aerosol treatment necessary in the pediatric emergency department? Chest 2000; 117:1309.</a></li><li><a class="nounderline abstract_t">Portnoy J, Nadel G, Amado M, Willsie-Ediger S. Continuous nebulization for status asthmaticus. Ann Allergy 1992; 69:71.</a></li><li><a class="nounderline abstract_t">Craig VL, Bigos D, Brilli RJ. Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. Pediatr Emerg Care 1996; 12:1.</a></li><li><a class="nounderline abstract_t">Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 21:1479.</a></li><li><a class="nounderline abstract_t">Montgomery VL, Eid NS. Low-dose beta-agonist continuous nebulization therapy for status asthmaticus in children. J Asthma 1994; 31:201.</a></li><li><a class="nounderline abstract_t">Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003; :CD001115.</a></li><li><a class="nounderline abstract_t">Rodrigo GJ, Rodrigo C. Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 2002; 122:160.</a></li><li><a class="nounderline abstract_t">Nievas IF, Anand KJ. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. J Pediatr Pharmacol Ther 2013; 18:88.</a></li><li><a class="nounderline abstract_t">Messer AF, Sampayo EM, Mothner B, et al. Continuous Albuterol in Pediatric Acute Care: Study Demonstrates Safety Outside the Intensive Care Unit. Pediatr Qual Saf 2019; 4:e225.</a></li><li><a class="nounderline abstract_t">Jat KR, Khairwa A. Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. Pulm Pharmacol Ther 2013; 26:239.</a></li><li><a class="nounderline abstract_t">Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29.</a></li><li><a class="nounderline abstract_t">Andrews T, McGintee E, Mittal MK, et al. High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. J Pediatr 2009; 155:205.</a></li><li><a class="nounderline abstract_t">Kercsmar CM, McDowell KM. Love it or lev it: levalbuterol for severe acute asthma--for now, leave it. J Pediatr 2009; 155:162.</a></li><li><a class="nounderline abstract_t">Phumeetham S, Bahk TJ, Abd-Allah S, Mathur M. Effect of high-dose continuous albuterol nebulization on clinical variables in children with status asthmaticus. Pediatr Crit Care Med 2015; 16:e41.</a></li><li><a class="nounderline abstract_t">Leung JS, Johnson DW, Sperou AJ, et al. A systematic review of adverse drug events associated with administration of common asthma medications in children. PLoS One 2017; 12:e0182738.</a></li><li><a class="nounderline abstract_t">Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001; :CD002178.</a></li><li><a class="nounderline abstract_t">Taylor DR, Hancox RJ. Interactions between corticosteroids and beta agonists. Thorax 2000; 55:595.</a></li><li><a class="nounderline abstract_t">Parikh K, Hall M, Mittal V, et al. Comparative Effectiveness of Dexamethasone versus Prednisone in Children Hospitalized with Asthma. J Pediatr 2015; 167:639.</a></li><li><a class="nounderline abstract_t">Becker JM, Arora A, Scarfone RJ, et al. Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol 1999; 103:586.</a></li><li><a class="nounderline abstract_t">Keeney GE, Gray MP, Morrison AK, et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. Pediatrics 2014; 133:493.</a></li><li><a class="nounderline abstract_t">Paniagua N, Lopez R, Muñoz N, et al. Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations. J Pediatr 2017; 191:190.</a></li><li><a class="nounderline abstract_t">Pound CM, McDonald J, Tang K, et al. Dexamethasone versus prednisone for children receiving asthma treatment in the paediatric inpatient population: protocol for a feasibility randomised controlled trial. BMJ Open 2018; 8:e025630.</a></li><li><a class="nounderline abstract_t">Normansell R, Kew KM, Mansour G. Different oral corticosteroid regimens for acute asthma. Cochrane Database Syst Rev 2016; :CD011801.</a></li><li><a class="nounderline abstract_t">Schuh S, Dick PT, Stephens D, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics 2006; 118:644.</a></li><li><a class="nounderline abstract_t">Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 2000; 343:689.</a></li><li><a class="nounderline abstract_t">Quon BS, Fitzgerald JM, Lemière C, et al. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev 2010; :CD007524.</a></li><li><a class="nounderline abstract_t">Tal A, Pasterkamp H, Leahy F. Arterial oxygen desaturation following salbutamol inhalation in acute asthma. Chest 1984; 86:868.</a></li><li><a class="nounderline abstract_t">Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo C. Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest 2003; 124:1312.</a></li><li><a class="nounderline abstract_t">Graham VA, Milton AF, Knowles GK, Davies RJ. Routine antibiotics in hospital management of acute asthma. Lancet 1982; 1:418.</a></li><li><a class="nounderline abstract_t">Normansell R, Sayer B, Waterson S, et al. Antibiotics for exacerbations of asthma. Cochrane Database Syst Rev 2018; 6:CD002741.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 09, 2008).</li><li><a class="nounderline abstract_t">Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database Syst Rev 2002; :CD001002.</a></li><li><a class="nounderline abstract_t">Wallis C, Prasad A. Who needs chest physiotherapy? Moving from anecdote to evidence. Arch Dis Child 1999; 80:393.</a></li><li><a class="nounderline abstract_t">Asher MI, Douglas C, Airy M, et al. Effects of chest physical therapy on lung function in children recovering from acute severe asthma. Pediatr Pulmonol 1990; 9:146.</a></li><li><a class="nounderline abstract_t">Craven D, Kercsmar CM, Myers TR, et al. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr 2001; 138:51.</a></li><li><a class="nounderline abstract_t">Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. Arch Pediatr Adolesc Med 2001; 155:1329.</a></li><li><a class="nounderline abstract_t">Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998; 339:1030.</a></li><li><a class="nounderline abstract_t">Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev 2014; :CD010283.</a></li><li><a class="nounderline abstract_t">Khan FI, Reddy RC, Baptist AP. Pediatric Dyspnea Scale for use in hospitalized patients with asthma. J Allergy Clin Immunol 2009; 123:660.</a></li><li><a class="nounderline abstract_t">Bhogal S, Zemek R, Ducharme FM. Written action plans for asthma in children. Cochrane Database Syst Rev 2006; :CD005306.</a></li></ol></div><div id="topicVersionRevision">Topic 5748 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for Disease Control and Prevenion (CDC). Most Recent National Asthma Data. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm (Accessed on August 28, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://hcupnet.ahrq.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Healthcare Cost and Utilization Project (HCUPnet). Agency for Healthcare Research and Quality, US Department of Health &amp; Human Services. Rockville, MD. https://hcupnet.ahrq.gov/ (Accessed on October 04, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/nchs/ahcd/about_ahcd.htm" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : National Ambulatory Medical Survey (NAMCS). Centers for Disease Control and Prevention (CDC), National Center for Health Stastistics (NCHS). https://www.cdc.gov/nchs/ahcd/about_ahcd.htm (Accessed on October 04, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/asthma.htm" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Asthma team CCHMC. Evidence based care guideline for managing an acute exacerbation of asthma. www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/asthma.htm (Accessed on February 08, 2008).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 08, 2008).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977987" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Quality of care for children hospitalized with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977987" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Quality of care for children hospitalized with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966133" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9043537" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evaluation of pre- and posttreatment pulse oximetry in acute childhood asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10386496" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pulse oximetry in the evaluation of the severity of acute asthma and/or wheezing in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14716161" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Difficulty in obtaining peak expiratory flow measurements in children with acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11825832" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Validation of the pulmonary score: an asthma severity score for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6720644" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The pulmonary index. Assessment of a clinical score for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15801246" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A modified pulmonary index score with predictive value for pediatric asthma exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8414819" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629678" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute asthma in the pediatric emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629678" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acute asthma in the pediatric emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8414852" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Safety of continuous nebulized albuterol for bronchospasm in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27305039" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Contemporary treatment of children with critical and near-fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781734" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Continuous intravenous terbutaline for pediatric status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/641628" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Myocardial ischemia complicating the use of isoproterenol in asthmatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3771954" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Myocardial specific creatine phosphokinase isoenzyme elevation in children with asthma treated with intravenous isoproterenol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27522309" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acute Management of Paradoxical Vocal Fold Motion (Vocal Cord Dysfunction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5644962" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Arterial-blood gas tension in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7110806" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An evaluation of the initial treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11536450" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of a pediatric asthma clinical pathway on hospital cost and length of stay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061767" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effectiveness of a clinical pathway for inpatient asthma management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18346499" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30795699" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Differentiating non-responders from responders in children with moderate and severe asthma exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15704591" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inpatient asthma clinical pathways for the pediatric patient: an integrative review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28096296" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A Critical Asthma Standardized Clinical and Management Plan Reduces Duration of Critical Asthma Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29664873" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of a PICU Status Asthmaticus De-Escalation Pathway on Length of Stay and Albuterol Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22536582" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22536582" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393600" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807815" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Is nebulized aerosol treatment necessary in the pediatric emergency department?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1626763" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Continuous nebulization for status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8677169" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8403956" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8195062" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Low-dose beta-agonist continuous nebulization therapy for status asthmaticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583926" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Continuous versus intermittent beta-agonists in the treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114352" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23798903" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32010852" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Continuous Albuterol in Pediatric Acute Care: Study Demonstrates Safety Outside the Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23207739" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15988423" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19464028" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19619747" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Love it or lev it: levalbuterol for severe acute asthma--for now, leave it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25560428" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of high-dose continuous albuterol nebulization on clinical variables in children with status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28793336" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A systematic review of adverse drug events associated with administration of common asthma medications in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279756" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Early emergency department treatment of acute asthma with systemic corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10856321" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Interactions between corticosteroids and beta agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26319919" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparative Effectiveness of Dexamethasone versus Prednisone in Children Hospitalized with Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10200005" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Oral versus intravenous corticosteroids in children hospitalized with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24515516" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dexamethasone for acute asthma exacerbations in children: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29173304" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30552284" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dexamethasone versus prednisone for children receiving asthma treatment in the paediatric inpatient population: protocol for a feasibility randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27176676" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Different oral corticosteroid regimens for acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16882819" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974132" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927759" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6499548" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Arterial oxygen desaturation following salbutamol inhalation in acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14555560" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6121090" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Routine antibiotics in hospital management of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29938789" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Antibiotics for exacerbations of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29938789" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antibiotics for exacerbations of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519548" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Manual therapy for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086954" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Who needs chest physiotherapy? Moving from anecdote to evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2277735" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effects of chest physical therapy on lung function in children recovering from acute severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148512" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11732951" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9761804" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of nebulized ipratropium on the hospitalization rates of children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25080126" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19181371" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pediatric Dyspnea Scale for use in hospitalized patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856090" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Written action plans for asthma in children.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
